A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain
Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to
receive CC-5013 10 mg/day orally. For each subject the study consists of two phases:
Pre-treatment phase(1 wk) and treatment phase (12 wks)